Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension

被引：4
|
作者：
Meyer, Gisela [1 ]
Galie, Nazzareno [1 ]
Grimminger, Friedrich [1 ]
Gruenig, Ekkehard [1 ]
Humbert, Marc [1 ]
Jing, Zhi-Cheng [1 ]
Keogh, Anne M. [1 ]
Langleben, David [1 ]
Rubin, Lewis J. [1 ]
Fritsch, Arno [1 ]
Davie, Neil [1 ]
Ghofrani, Hossein-Ardeschir [1 ]
机构：
[1] Complexo Hosp Santa Casa Porto Alegre, Ctr Hipertensao Pulm, Porto Alegre, RS, Brazil
来源：
CHEST | 2014年 / 145卷 / 03期
关键词：
D O I：
10.1378/chest.1824389
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
513A
引用
收藏
页数：3
相关论文
共 42 条
  • [31] LONG-TERM SAFETY AND EFFICACY OF ORAL EVEROLIMUS IN THE TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS IN TUBEROUS SCLEROSIS COMPLEX: RESULTS FROM AN OPEN-LABEL, EXTENSION PHASE OF A PROSPECTIVE, PHASE I-II STUDY
    Krueger, D. A.
    Care, M. M.
    Holland-Bouley, K.
    Agricola, K.
    Tudor, C.
    Mangeshkar, P.
    Wilson, K.
    Weber-Byars, A.
    Sahmoud, T.
    Franz, D. N.
    EPILEPSIA, 2011, 52 : 11 - 11
  • [32] Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab
    Umezawa, Y.
    Torisu-Itakura, H.
    Morisaki, Y.
    ElMaraghy, H.
    Nakajo, K.
    Akashi, N.
    Saeki, H.
    Akasaka, Toshihide
    Asano, Yoshihide
    Etoh, Takafumi
    Fujita, Yasuyuki
    Hashimoto, Takashi
    Higashiyama, Mari
    Igarashi, Atsuyuki
    Ihn, Hironobu
    Iwatsuki, Keiji
    Kabashima, Kenji
    Kawada, Akira
    Kawashima, Makoto
    Nakamura, Koichiro
    Okubo, Yukari
    Okuyama, Ryuhei
    Ozawa, Akira
    Sayama, Koji
    Seishima, Mariko
    Shiohara, Tetsuo
    Takahara, Masakazu
    Takahashi, Hidetoshi
    Takehara, Kazuhiko
    Tanese, Keiji
    Tani, Mamori
    Umezawa, Yoshinori
    Watanabe, Hideaki
    Yamanaka, Keiichi
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) : 568 - 576
  • [33] Long-Term Efficacy and Safety of Teduglutide Treatment for Patients with Intestinal Failure Associated with Short Bowel Syndrome: Final Results From STEPS-2, a 24-Month, Multicenter, Open-Label, Phase III Extension Study
    Jeppesen, Palle
    Fujioka, Ken
    Youssef, Nader N.
    O'Keefe, Stephen J.
    TRANSPLANTATION, 2015, 99 : S2 - S2
  • [34] Long-Term Efficacy and Safety of Intravenous (IV) Tulisokibart in Patients With Crohn's Disease (CD): Results from the Open-Label Extension Period of the Phase 2 APOLLO-CD Study
    Siegel, Corey A.
    Leong, Rupert W.
    Anderson, Jaclyn K.
    Yen, Mark
    Dong, Bin
    Sands, Bruce E.
    Danese, Silvio
    Feagan, Brian G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1000 - S1000
  • [35] Long-Term Efficacy and Safety of Intravenous (IV) Tulisokibart in Patients With Ulcerative Colitis (UC): Results From the Open-Label Extension (OLE) Period of the Phase 2 ARTEMIS-UC Study
    Ma, Christopher
    Hoque, Sami
    Sparrow, Miles P.
    Anderson, Jaclyn K.
    Yen, Mark
    Dong, Bin
    Feagan, Brian G.
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1046 - S1047
  • [36] DISEASE ACTIVITY AND SAFETY DURING LONG-TERM (104-WEEK) TREATMENT WITH APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 3)
    Edwards, C.
    Blanco, F.
    Crowley, J.
    Hu, C.
    Shah, K.
    Birbara, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 348 - 349
  • [37] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn's Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S466 - S466
  • [38] Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study
    Sardh, Eliane
    Balwani, Manisha
    Rees, David C.
    Anderson, Karl E.
    Jia, Gang
    Sweetser, Marianne T.
    Wang, Bruce
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [39] Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/ INS)
    Terauchi, Yasuo
    Tamura, Masahiro
    Senda, Masayuki
    Gunji, Ryoji
    Kaku, Kohei
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1176 - 1185
  • [40] Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis
    Yamanaka, Hisashi
    Tanaka, Yoshiya
    Hibino, Toshihiko
    Unmesh, Gopalakrishnan
    Shah, Chirag
    Bakhle, Dhananjay
    Stefanidis, Dimitris
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (01) : 108 - 115
12345